Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Down 25.8% in December

by · The Markets Daily

Ensysce Biosciences, Inc. (NASDAQ:ENSC – Get Free Report) saw a significant decline in short interest in December. As of December 31st, there was short interest totaling 166,971 shares, a decline of 25.8% from the December 15th total of 225,167 shares. Based on an average trading volume of 133,308 shares, the short-interest ratio is currently 1.3 days. Approximately 4.7% of the company’s stock are sold short. Approximately 4.7% of the company’s stock are sold short. Based on an average trading volume of 133,308 shares, the short-interest ratio is currently 1.3 days.

Institutional Investors Weigh In On Ensysce Biosciences

Several large investors have recently made changes to their positions in the business. TRU Independence Asset Management 2 LLC bought a new stake in shares of Ensysce Biosciences during the 3rd quarter worth $25,000. Citadel Advisors LLC bought a new position in Ensysce Biosciences during the third quarter valued at about $34,000. Finally, Virtu Financial LLC purchased a new stake in Ensysce Biosciences during the third quarter worth about $34,000. 5.63% of the stock is owned by hedge funds and other institutional investors.

Ensysce Biosciences Stock Down 6.5%

ENSC stock traded down $0.06 during trading on Friday, reaching $0.84. The stock had a trading volume of 108,051 shares, compared to its average volume of 104,386. The company has a market capitalization of $3.06 million, a price-to-earnings ratio of -0.13 and a beta of 1.15. Ensysce Biosciences has a one year low of $0.82 and a one year high of $8.97. The company’s 50 day moving average is $1.39 and its two-hundred day moving average is $1.91.

Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) last announced its earnings results on Friday, November 14th. The company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.44). The business had revenue of $0.49 million during the quarter, compared to analysts’ expectations of $0.70 million. Ensysce Biosciences had a negative return on equity of 437.31% and a negative net margin of 244.47%. As a group, research analysts predict that Ensysce Biosciences will post -8.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ENSC shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded Ensysce Biosciences to a “hold” rating in a report on Saturday, October 25th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Ensysce Biosciences presently has an average rating of “Sell”.

View Our Latest Stock Report on Ensysce Biosciences

Ensysce Biosciences Company Profile

(Get Free Report)

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.

Featured Articles